Headquartered in Singapore, Takeda's Growth & Emerging Markets Business Unit (GEM BU) has presence in almost 50 geographies that includes two key countries Brazil and Russia, and three Geographical Areas operations with hubs in Asia Pacific, ICMEA, and SAM*.
In line with Takeda’s global strategy, GEM BU is focused on delivering highly innovative medicines to patients living with complex and rare diseases in its five key business areas – Gastroenterology, Rare Diseases, Plasma-Derived Therapies, Oncology and Neuroscience.
We strive to do so via an ‘Access First’ mindset that aims to ‘fast track’ patient access to life-transforming medicines across a region of over
5 billion people, which represents almost 65% of the world population, via accelerating product launches and the expansion of appropriate local-specific initiatives via Takeda’s global Access to Medicines programs.
GEM BU is committed to working with strategic partners across the region, including governments, patient organizations and healthcare regulators, to accelerate patient access, address unmet patient needs, drive future growth, and ensure a sustainable business.
The BU aspires to be viewed as 'Best in Class' in the eyes of patients, customers and its own employees. Over the recent years, many of its local offices across the region have been externally recognized as a ‘Top Employer’ by the Top Employer Institute.
*APAC - Asia Pacific
ICMEA - India, CIS, the Middle East, including Turkey, & Africa
SAM - South Cone, Andean and Mexico
TAKEDA PHARMACEUTICALS INTERNATIONAL AG SINGAPORE BRANCH
8 Marina Boulevard, #15-01 Marina Bay Financial Centre, Singapore 018981